Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes
NCT02548494 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17
Last updated 2020-09-23
Summary
The management goals of diabetic ketoacidosis (DKA) in the pediatric type 1 diabetes (T1DM) population are fluid and electrolyte repletion, insulin administration, and correction of acidosis in order to stabilize the patient. Traditionally, a rapid-acting insulin IV infusion is begun immediately and continued until the acidosis is corrected and hyperglycemia normalized. Once the acidosis is corrected, patients are able to be transitioned to a subcutaneous insulin regimen.
The role that a subcutaneous long-acting insulin such as glargine has in the acute treatment of DKA has not been extensively studied. While giving glargine during the treatment of DKA is becoming more common place, few studies have examined the potential risks and benefits of its use. This study will investigate the effects of early administration of glargine during DKA in patients with newly diagnosed TIDM.
The design of this study is a prospective, double-blind study of children ages 2-21 who are admitted to the hospital in DKA with a diagnosis of T1DM. The control group will receive all traditional methods of treatment for DKA, including a placebo subcutaneous injection. The study group will receive the same treatment, but will be supplemented with a subcutaneous glargine injection.
Conditions
- Diabetes Mellitus, Type 1
- Diabetic Ketoacidosis
Interventions
- DRUG
-
Glargine
The control group will receive all traditional methods of treatment for DKA, including a placebo subcutaneous injection. The study group will receive the same treatment, but will be supplemented with a subcutaneous glargine injection.
- DRUG
-
IV insulin
The intravenous infusion of insulin at a weight-based fixed rate until ketosis has subsided.
- OTHER
-
Electrolyte Correction
If the potassium level is greater than 6 mEq/L, do not administer potassium supplement. If the potassium level is 4.5-6 mEq/L, administer 10 mEq/h of potassium chloride. If the potassium level is 3-4.5 mEq/L, administer 20 mEq/h of potassium chloride.
- OTHER
-
Correction of Fluid Loss
Initial correction of fluid loss is either by isotonic sodium chloride solution or by lactated Ringer solution. The recommended schedule for restoring fluids is as follows: * Administer 1-3 L during the first hour. * Administer 1 L during the second hour. * Administer 1 L during the following 2 hours * Administer 1 L every 4 hours, depending on the degree of dehydration and central venous pressure readings
Sponsors & Collaborators
-
Chattanooga-Hamilton County Hospital Authority
lead OTHER
Principal Investigators
-
Rita Shridharani, MD · UTCOMC/ Children's at Erlanger
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 1 Year
- Max Age
- 21 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-11-30
- Primary Completion
- 2019-02-01
- Completion
- 2019-02-01
Countries
- United States
Study Locations
More Related Trials
-
Insulin Resistance in Type I Diabetes in Pediatric Care
NCT00946426 ·Status: WITHDRAWN
-
Intermediate and Long Acting Insulin Young Children Type 1 Diabetes.
NCT04664764 ·Status: UNKNOWN ·Phase: PHASE4
-
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
NCT01513473 ·Status: COMPLETED ·Phase: PHASE3
-
Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis
NCT01271517 ·Status: UNKNOWN ·Phase: PHASE4
-
The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)
NCT00004984 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes
NCT02670915 ·Status: COMPLETED ·Phase: PHASE3
-
Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)
NCT00357890 ·Status: COMPLETED ·Phase: NA
-
Suppression of Endogenous Glucose Production by Injectable HDV-Insulin Lispro: A Dose Response Study in Human Subjects With Type 1 Diabetes
NCT05689424 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Risk Factors of Metabolic Control in Children and Adolescents With Type 1 Diabetes
NCT03642470 ·Status: COMPLETED
-
Comparison of an Artificial Pancreas Versus Threshold Low Glucose Suspend in Type 1 Diabetic Children
NCT02509429 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Pulsed Intravenous (IV) Insulin on Brittle and Uncontrolled Diabetes
NCT01029444 ·Status: TERMINATED ·Phase: PHASE3
-
Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents
NCT02402933 ·Status: COMPLETED ·Phase: PHASE3
-
T1 Diabetes Hypoglycemia Prevention Pilot
NCT02682940 ·Status: TERMINATED ·Phase: NA
-
Hematopoietic Stem Cell Support Versus Insulin in T1D
NCT01285934 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus
NCT04157738 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of an Early Screener to Identify Long-term Problems With Regard to Metabolic Control and Treatment Adherence Among Children and Adolescents With Type 1 Diabetes
NCT03642483 ·Status: COMPLETED
-
Prevention of Skin Problems With Diabetes Devices in Pediatric Patients
NCT04258904 ·Status: COMPLETED ·Phase: NA
-
A Multi-Disciplinary Technology-Based Care for Diabetic Ketoacidosis in Patients With Type 1 Diabetes
NCT06471322 ·Status: TERMINATED ·Phase: NA
-
Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose
NCT04623086 ·Status: COMPLETED ·Phase: PHASE4
-
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
NCT04259775 ·Status: WITHDRAWN ·Phase: NA
-
A Pilot Study to Evaluate the Safety of Terbutaline in Children With Type 1 Diabetes
NCT00607503 ·Status: COMPLETED ·Phase: PHASE1
-
Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses
NCT03490942 ·Status: TERMINATED ·Phase: PHASE2
-
A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001)
NCT02269735 ·Status: COMPLETED ·Phase: PHASE1
-
Additional Insulin for Fat and Protein in Children With Diabetes Study
NCT02680054 ·Status: TERMINATED ·Phase: PHASE4
-
Efficacy of Automated Insulin Therapy Early Initiated After Diagnosis on Blood Glucose Control in Children and Adolescents With Type 1 Diabetes
NCT06283797 ·Status: RECRUITING ·Phase: NA